Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009

ad a strong cash position of EUR52.6 million. This compares to EUR40.1 million in cash and EUR6.7 million in short term investments at 30 June 2008.

These funds will allow ThromboGenics to support its business for approximately the next two years. The Company's underlying cash burn is expected to increase given the continuing investment in the Phase III program for microplasmin in eye disease, as well as the start of ThromboGenics own commercial activities to ensure the successful launch of this exciting new product.

At the end of June 2009, ThromboGenics had total shareholders equity of EUR61.1 million which compares with EUR67.6 million at the end of June 2008.

ThromboGenics experienced a EUR4.6 million cash outflow in the first half of 2009. This compares with a cash outflow of EUR8.1 million in the first half of 2008, when the Company was still awaiting payment of the EUR30 million upfront payment from Roche.

    Unaudited consolidated statement of profit and loss


               Unaudited consolidated statement of profit and loss

                                              Half year         Half year
    In '000 Euro, except per share amounts    6 months          6 months
              According to IFRS            Jan - June 2009   Jan - June 2008
    Income                                           3,609            30,298
                            License income           3,549            30,255
                            Royalty income              54                 -
                              Other income               6                43
    Cost of sales                                     (454)              (29)
    Gross profit                                     3,155            30,269
    Research and development expenses               (8,842)          (11,582)
    General and administrative expenses            
SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
(Date:7/31/2015)... 2015 In today,s fast changing healthcare ... drive positive health outcomes, improve profitability and enhance ... care in their communities. At ThoughtSpot 2015, ... AmerisourceBergen announced a new set of innovative capabilities ... and help independent pharmacies endure the industry,s most ...
(Date:7/31/2015)... ... July 31, 2015 , ... Global ... and premium industry insights on the global resorcinol industry. The report highlights the ... of vivid market scenarios and analysis of primary and secondary inputs from the ...
(Date:7/31/2015)... 31, 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, ... today announced that the Company has filed its Annual ... Exchange Commission. The filed Form 20-F includes audited financial ... The Form 20-F can be accessed by visiting the ...
(Date:7/31/2015)... ... July 31, 2015 , ... R-Biopharm is proud to announce ... gluten in foods, has been accepted by AOAC International as Official First Action ... Fermented Cereal-Based Products by R5 Competitive ELISA,” based on a specific monoclonal antibody ...
Breaking Biology Technology:AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at 4China Cord Blood Corporation Files Its Annual Report on Form 20-F 2RIDASCREEN® Competitve Gliadin Receives AOAC Official First Action Status 2
... September 20, 2011 Silence Therapeutics plc ... leading global RNA interference (RNAi) therapeutics company, today announces ... with immediate effect. He will be based at Silence,s ... brings more than 20 years experience in corporate and ...
... be the nation,s next "Strontium Valley"? The University of Pittsburgh ... the National Science Foundation and the Nanoelectronics Research Initiative (NRI) ... kind of computer out of the lab and into the ... Levy, a professor of physics and astronomy in Pitt,s School ...
... Imagenetix, Inc. (OTCBB: IAGX) announced today that it received ... out of its pending dispute with former distributor TriPharma, ... pending before a private arbitrator and is conducted under ... in San Diego, California.  The interim award against the ...
Cached Biology Technology:Appointment of Chief Executive Officer 2Appointment of Chief Executive Officer 3Appointment of Chief Executive Officer 4Post-silicon computing 2Post-silicon computing 3Post-silicon computing 4
(Date:7/9/2015)... Calif. , July 9, 2015  Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... Thursday, July 30, 2015 after the close of market. ... analysts and investors at 2:00 p.m. PT (5:00 p.m. ... To participate on the live call, analysts ...
(Date:7/8/2015)... NEW YORK , July 8, 2015 ... cancer globally, and the fourth most fatal, with a ... year. The poor prognosis of pancreatic cancer patients has ... to treatment, which is not being met by the ... contains an array of products with varying molecule types ...
(Date:7/7/2015)... 2015 Research and ... of the "Capacitive Fingerprint Sensors Patent Landscape" ... this date, fingerprint sensing technology is the most ... are well developed. This patent landscape focuses on ... The domain of capacitive fingerprint sensors is closely ...
Breaking Biology News(10 mins):Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... MD FASEB MARC (Minority Access to Research Careers) ... 2011 Society for Leukocyte Biology (SLB) Meeting in Kansas ... are meant to promote the entry of underrepresented minority ... basic science community and to encourage the participation of ...
... Technologies Inc. have signed a cooperative research and development ... Imaging Technologies, FlowCAM instrument to detect and document quagga ... spread of mussels throughout the western United States has ... hydropower generation functions as well as create long-term ecological ...
... Mass. -- A major challenge for cancer biologists is figuring ... a cancer cell are most important for driving the cancer,s ... MIT scientists have now pinpointed a gene that appears to ... of lung cancer accounting for about 15 percent of lung ...
Cached Biology News:Reclamation signs research agreement to improve quagga and zebra mussel larvae detection 2New lung-cancer gene found 2
... time consuming and inaccurate comparison of the entire ... of the sample when compared to the wild ... as a sharp peak. Accuracy of the ... 99%, with sensitivity to greater than 5% of ...
... is used to coat the inner wall of ... source of the DNA that enters target cells ... The station includes a tubing support cylinder, power ... nitrogen regulator hose, two 0.1875 inch barb-to-male Luer-Lok ...
... Helios gene gun low-pressure system, 220-240 V, is ... cells. This handheld device employs an adjustable helium ... gold microcarriers from the inner wall of a ... system can be used for in situ, in ...
... 220-240 V, is used for biolistic particle ... device employs an adjustable helium pulse to ... microcarriers from the inner wall of a ... This system has a 2 square-centimeter target ...
Biology Products: